Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects.

The success of an effective drug delivery system using liposomes for solid tumor targeting based on EPR effects is highly dependent on both size ranging from 100-200 nm in diameter and prolonged circulation half-life in the blood. A major development was the synthesis of PEG-liposomes with a prolonged circulation time in the blood. Active targeting of immunoliposomes to the solid tumor tissue can be achieved by the Fab' fragment which is better than whole IgG in terms of designing PEG-immunoliposomes with prolonged circulation. For intracellular targeting delivery to solid tumors based on EPR effects, transferrin-PEG-liposomes can stay in blood circulation for a long time and extravasate into the extravascular of tumor tissue by the EPR effect as PEG-liposomes. The extravasated transferrin-PEG-liposomes can maintain anti cancer drugs in interstitial space for a longer period, and deliver them into the cytoplasm of tumor cells via transferrin receptor-mediated endocytosis. Transferrin-PEG-liposomes improve the safety and efficacy of anti cancer drug by both passive targeting by prolonged circulation and active targeting by transferrin.

[1]  L. Huang,et al.  Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. , 1995, Biochimica et biophysica acta.

[2]  T. Allen.  Liposomal Drug Formulations , 1998, Drugs.

[3]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[4]  T. Boulikas,et al.  Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. , 2005, Oncology reports.

[5]  G Blume,et al.  Liposomes for the sustained drug release in vivo. , 1990, Biochimica et biophysica acta.

[6]  Tamar Safra.  Cardiac safety of liposomal anthracyclines. , 2003, The oncologist.

[7]  D. Friend,et al.  Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. , 1992, Cancer research.

[8]  K. Maruyama,et al.  Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathic poly(ethylene glycol) , 1995 .

[9]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[10]  Jörg Huwyler,et al.  Tumor targeting using liposomal antineoplastic drugs , 2008, International journal of nanomedicine.

[11]  M. Hawthorne.  The Role of Chemistry in the Development of Boron Neutron Capture Therapy of Cancer , 1993 .

[12]  S. Moghimi,et al.  Opsonophagocytosis of liposomes by peritoneal macrophages and bone marrow reticuloendothelial cells. , 1992, Biochimica et biophysica acta.

[13]  V. Torchilin,et al.  Characterization of in vivo immunoliposome targeting to pulmonary endothelium. , 1990, Journal of pharmaceutical sciences.

[14]  T M Allen,et al.  Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.

[15]  Ulrich Beyer,et al.  Liposomal encapsulated anti-cancer drugs. , 2005, Anti-cancer drugs.

[16]  H. Kikuchi,et al.  Phosphatidyl polyglycerols prolong liposome circulation in vivo , 1994 .

[17]  H. Maeda.  The tumor blood vessel as an ideal target for macromolecular anticancer agents , 1992 .

[18]  Matthew Cotten,et al.  Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis , 1994 .

[19]  Y. Koyanagi,et al.  Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy , 1996 .

[20]  T. Allen,et al.  Improved Outcome When B-Cell Lymphoma Is Treated with Combinations of Immunoliposomal Anticancer Drugs Targeted to Both the CD19 and CD20 Epitopes , 2004, Clinical Cancer Research.

[21]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[22]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[23]  M. Bally,et al.  A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form , 2001, Drug safety.

[24]  L. Leserman,et al.  Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[25]  H. Laborit,et al.  [Cytotoxicity]. , 2018, Agressologie: revue internationale de physio-biologie et de pharmacologie appliquees aux effets de l'agression.

[26]  Vladimir P Torchilin,et al.  Passive and active drug targeting: drug delivery to tumors as an example. , 2010, Handbook of experimental pharmacology.

[27]  H. Sharata,et al.  Liposomes , 2017, Methods in Molecular Biology.

[28]  K. Maruyama,et al.  Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). , 1992, Biochimica et biophysica acta.

[29]  G. Scherphof,et al.  UPTAKE AND PROCESSING OF IMMUNOGLOBULIN-COATED LIPOSOMES BY SUBPOPULATIONS OF RAT-LIVER MACROPHAGES , 1988 .

[30]  A. Gabizon.  Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[31]  H. Yanagie,et al.  Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT). , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[32]  K. Maruyama,et al.  Novel Immunoliposomes Modified with Amphipathic Polyethyleneglycols Conjugated at their Distal Terminals to Monoclonal Antibodies , 1996 .

[33]  M. Beeram,et al.  A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  I. Romslo,et al.  The transferrin receptor: its diagnostic value and its potential as therapeutic target. , 1993, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[35]  Y. Eishi,et al.  Transferrin receptor in oral tumors. , 1994, International journal of oral and maxillofacial surgery.

[36]  M. Frank.  The reticuloendothelial system and bloodstream clearance. , 1993, The Journal of laboratory and clinical medicine.

[37]  H. Dvorak,et al.  Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. , 1988, The American journal of pathology.

[38]  K. Maruyama,et al.  Immunoliposomes bearing polyethyleneglycol‐coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo , 1997, FEBS letters.

[39]  D. Papahadjopoulos,et al.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.

[40]  J. Drevs,et al.  Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study , 2004, Cancer Chemotherapy and Pharmacology.

[41]  G. Hofstede,et al.  Liposomal doxorubicin‐induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages , 1995, International journal of cancer.

[42]  T. Allen,et al.  Pharmacokinetics of stealth versus conventional liposomes: effect of dose. , 1991, Biochimica et biophysica acta.

[43]  R. Perez,et al.  Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. , 1995, Cancer letters.

[44]  Kazuo Maruyama,et al.  Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. , 2008, International journal of pharmaceutics.

[45]  L. Huang,et al.  Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. , 1992, Biochimica et biophysica acta.

[46]  W. Pardridge,et al.  Brain drug delivery and blood–Brain barrier transport , 1993 .

[47]  T. Boulikas,et al.  The challenge of liposomes in gene therapy , 1998 .

[48]  L. Huang,et al.  Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo. , 1992, Biochimica et biophysica acta.

[49]  H. Shmeeda,et al.  Pros and Cons of the Liposome Platform in Cancer Drug Targeting , 2006, Journal of liposome research.

[50]  K. Maruyama,et al.  Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. , 1999, International journal of pharmaceutics.

[51]  Maruyama,et al.  Possibility of active targeting to tumor tissues with liposomes. , 1999, Advanced drug delivery reviews.

[52]  R. Barth,et al.  Boron neutron capture therapy for cancer. , 1990, Scientific American.

[53]  C. Benz,et al.  Future directions of liposome- and immunoliposome-based cancer therapeutics. , 2004, Seminars in oncology.

[54]  T. Tadakuma,et al.  Improvement of Therapeutic Effect by Using Fab' Fragment in the Treatment of Carcinoembryonic Antigen‐positive Human Solid Tumors with Adriamycinentrapped Immunoliposomes , 1994, Japanese journal of cancer research : Gann.

[55]  L Biganzoli,et al.  EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  G. Scherphof,et al.  Uptake and processing of immunoglobulin-coated liposomes by subpopulations of rat liver macrophages. , 1988, Biochimica et biophysica acta.

[57]  H. Maeda,et al.  Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. , 1992, Bioconjugate chemistry.

[58]  A. Soloway,et al.  Boron neutron capture therapy for cancer. Realities and prospects , 1992 .

[59]  S. Hirota,et al.  Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome. , 2002, International journal of pharmaceutics.

[60]  M. Bally,et al.  Controlling the Physical Behavior and Biological Performance of Liposome Formulations Through Use of Surface Grafted Poly(ethylene Glycol) , 2002, Bioscience reports.

[61]  Rakesh K. Jain,et al.  Transport of molecules across tumor vasculature , 2004, Cancer and Metastasis Reviews.